Table II.
Treatment Characteristics and Prognosis of the HPC and SPC Patients
| HPC patients (N = 321) | SPC patients (N = 1,664) | Difference | |||
|---|---|---|---|---|---|
| Primary treatment | |||||
| Active surveillance | 22 | 6.9 | 227 | 13.7 | |
| Localized therapy | |||||
| RP | 130 | 40.5 | 600 | 36.1 | |
| Cryotherapy | – | 3 | 0.2 | ||
| Radiation therapy | 66 | 20.6 | 183 | 11.0 | |
| EBRT | 34 | 10.6 | 123 | 7.4 | |
| Brachytherapy | 32 | 10.0 | 60 | 3.6 | |
| RP + RT | 2 | 0.6 | 5 | 0.3 | |
| Systemic therapy | |||||
| RP + HT | 5 | 1.6 | 16 | 1.0 | |
| EBRT + HT | 50 | 15.6 | 288 | 17.3 | |
| HT monotherapy | 37 | 11.5 | 323 | 19.4 | |
| Chemotherapy | – | – | 1 | 0.1 | |
| Other therapy | – | – | 3 | 0.2 | |
| Unknown | 8 | 2.5 | 15 | 0.9 | |
| Progression after RP a | |||||
| 5‐year progression‐free survival | 78% | (95%CI 71–86%) | 74% | (95%CI 69–77%) | P = 0.30 b |
| Survival | |||||
| 5‐year overall survival | 85% | (95%CI 81–89%) | 80% | (95%CI 78–82%) | P = 0.03 b |
| 5‐year relative survival | 98% | (95%CI 94–100%) | 90% | (95%CI 88–92%) | |
EBRT, external‐beam radiation therapy; HT, hormonal therapy; RP, radical prostatectomy; RT, radiation therapy.
a
Progression after RP was defined as the occurrence of any of the following events: biochemical recurrence, that is, two serum PSA measurements ≥ 0.2 ng/ml; histological evidence of local recurrence; initiation of salvage treatment (e.g., radiation therapy) without documented evidence of biochemical recurrence; detection of metastatic disease.
b
χ2 testing with generalized estimating equations in a proportional‐hazards model was used to test for differences in survival.